top of page

PUBLICATIONS

This page features NeoVac’s scientific outputs. Peer-reviewed papers, conference presentations, posters and other publications. For company news and announcements, please see News.

Preclinical Evaluation and Phase I Clinical Trial of Neomivac, a Lipid Nanoparticle mRNA Vaccine

SSRN, 2026

Don’t shoot the messenger: Non‑viral delivery’s real‑world revolution

Cell & Gene Therapy Insights, 2026

Advanced Quality and Comparability Assessment of mRNA-Loaded Lipid Nanoparticles

ACS Publications, 2026

Inside NeoVac's LNP Formulation Strategy: Challenges, Innovation, And What Comes Next

Advancing RNA, 2025

The impact of chemical reactivity on the quality and stability of RNA–LNP pharmaceuticals

Nature Reviews, 2025

Novel Bivalent mRNA-LNP Vaccine for Highly Effective
Protection against Pneumonic Plague

Advanced Science, 2025

Ionizable Lipids with Optimized Linkers Enable Lung-Specific, Lipid Nanoparticle Mediated mRNA Delivery for Treatment of Metastatic Lung Tumors

ACS Nano, 2025

Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery

ACS Applied Nano Materials, 2020

A single-dose F1-based mRNA-LNP vaccine provides
protection against the lethal plague bacterium

Science Advances, 2023

Lipid Nanoparticles With Fine-Tuned Composition Show
Enhanced Colon Targeting as a Platform for mRNA Therapeutics

Advanced Science, 2024

A Combinatorial Library of Lipid Nanoparticles for RNA
Delivery to Leukocytes

Advanced Materials, 2020

bottom of page